Help us: Donate
Follow us on:




Nanoparticles in blood
December 02, 2020
Scientists have successfully tested a new nanoparticle-based delivery system for CRISPR kits, achieving drastic improvements in mouse models of glioblastoma and ovarian cancer [1]. A gift from our single-cell ancestors CRISPR gene editing technology has been widely hailed as a potential game changer in medicine, including anti-cancer therapy. CRISPR’s ability to permanently disrupt tumor survival...
Gene segment
October 19, 2020
Researchers have successfully used the CRISPR/Cas9 gene editing tool to destroy Ewing's sarcoma and chronic myeloid leukemia tumor cells by targeting the fusion genes responsible for these tumors [1]. Fusion genes, a feature in many different types of cancer, arise when a mutation fuses two genes together, which typically happens when the DNA sequence between...
A picture of brown fat cells
September 08, 2020
A group of researchers has used CRISPR to create energy-dissipating brown adipocytes (fat cells) from white preadipocytes. The new cells were then shown to alleviate obesity in mice [1]. Obesity: the nemesis of longevity Obesity is one of humanity’s deadliest enemies. It is a known comorbidity in a plethora of diseases, including age-related, such as...
July 14, 2020
Researchers have developed what can be described as the first precision gene editing tool for mitochondrial DNA (mtDNA). This new tool is different from the well-known CRISPR/Cas9 method of gene editing and should make the study of mitochondrial biology and mitochondrial diseases easier. This new discovery is a game changer Prior to this, creating mouse...
Gene tweezers
March 31, 2020
Researchers have overcome a major limitation of the CRISPR-Cas9 gene editing system, which should allow previously inaccessible parts of the genome to be edited with ease. What is CRISPR-Cas9? Clustered regularly interspaced short palindromic repeats (CRISPR) is used in CRISPR-Cas9 and CRISPR-associated protein, a gene editing system that has created considerable excitement in the last...
February 28, 2020
The successful delivery of CRISPR/Cas9 modified immune cells to cancer patients represents the first U.S. clinical trial to test the gene editing approach in humans. Researchers from the Abramson Cancer Center of the University of Pennsylvania have published data suggesting that immune cells modified using the gene editing tool CRISPR/Cas9 are able to survive and...